Lv2
170 积分 2023-10-07 加入
Aggregation Mechanism of an IgG2 and two IgG1 Monoclonal Antibodies at low pH: From Oligomers to Larger Aggregates
2天前
已完结
Protein aggregation and mitigation strategy in low pH viral inactivation for monoclonal antibody purification
2天前
已完结
Effects of acid exposure on the conformation, stability, and aggregation of monoclonal antibodies
2天前
已完结
Impact of residual impurities and contaminants on protein stability
29天前
已完结
Human monoclonal antibody stability and activity at vaginal pH
1个月前
已完结
Biophysical properties of the clinical-stage antibody landscape
1个月前
已完结
Qualification of impurities based on metabolite data
1个月前
已完结
HMDB 5.0: the Human Metabolome Database for 2022
1个月前
已完结
Safety risk management for low molecular weight process-related impurities in monoclonal antibody therapeutics: Categorization, risk assessment, testing strategy, and process development with leveraging clearance potential
1个月前
已完结
Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing
1个月前
已完结
皖公网安备34019202002308
